<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM25C56-6TM-R8-FLP"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S3510 IS: Biosimilar Inspection Modernization Act of 2025</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-12-16</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress>
 <session>1st Session</session><legis-num>S. 3510</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20251216">December 16, 2025</action-date><action-desc><sponsor name-id="S417">Mr. Budd</sponsor> (for himself and <cosponsor name-id="S388">Ms. Hassan</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To improve the inspections of drug establishments engaged in the manufacture, preparation, propagation, or processing of biosimilar biological products conducted by the Food and Drug Administration, and for other purposes.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Biosimilar Inspection Modernization Act of 2025</short-title></quote>.</text></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="id9ab8c51e2b7a42578278cc48e8275509"><enum>2.</enum><header display-inline="yes-display-inline">Definitions</header><text display-inline="no-display-inline">In this Act—</text><paragraph commented="no" display-inline="no-display-inline" id="id2ae894bff3d14343ad6b3962684f1bc6"><enum>(1)</enum><text display-inline="yes-display-inline">the term <term>biosimilar biological product</term> means a biological product licensed under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>);</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id180ba66576884cac98d19e7bc605ef4d"><enum>(2)</enum><text display-inline="yes-display-inline">the term <term>biosimilar biological product establishment</term> means an establishment engaged in the manufacture, preparation, propagation, or processing of a biosimilar biological product and registered under subsection (b)(1), (c)(1), or (i) of section 510 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360</external-xref>); and</text></paragraph><paragraph id="idf2b2a84381e84f6d92277fff6ad165e0" commented="no" display-inline="no-display-inline"><enum>(3)</enum><text>the term <term>Secretary</term> means the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs.</text></paragraph></section><section commented="no" display-inline="no-display-inline" id="idccdeb3242f064eb3a47dab6d2d5e4571"><enum>3.</enum><header>Public meeting and report on mutual recognition agreements</header><subsection commented="no" display-inline="no-display-inline" id="idfc4e1cfb13ce412aac67938b495795cf"><enum>(a)</enum><header display-inline="yes-display-inline">Public meeting</header><text display-inline="yes-display-inline">Not later than 180 days after the date of enactment of this Act, the Secretary shall conduct a public meeting on the use of mutual recognition agreements for purposes of carrying out inspections under section 704 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374</external-xref>) of establishments engaged in the manufacture, preparation, propagation, or processing of a biosimilar biological product, including a discussion of—</text><paragraph id="id606b837e0b73433fa79724fe7ffe5032"><enum>(1)</enum><text>how mutual recognition agreements are utilized with respect to the inspection of biosimilar biological product establishments, and areas for improvements in such inspections conducted pursuant to such agreements; and</text></paragraph><paragraph id="idcdb616a027d3472889021b5a12721bdd"><enum>(2)</enum><text>areas in which use of mutual recognition agreements could be expanded to apply beyond compliance inspections under section 704 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374</external-xref>), including for use in conjunction with remote regulatory assessments, inspections conducted by trusted foreign partners identified by the Food and Drug Administration, and virtual interactions with subject matter experts.</text></paragraph></subsection><subsection id="idbae26fe3fad243e483b55e37ab59a350"><enum>(b)</enum><header>Report</header><text>Not later than 180 days after the public meeting under subsection (a) is conducted, the Secretary shall issue to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and make publicly available, a report that includes recommendations on the use of mutual recognition agreements for purposes of conducting inspections of biosimilar biological product establishments.</text></subsection></section><section commented="no" display-inline="no-display-inline" id="id217019e2dd7e449db6943ac4bc3e1829"><enum>4.</enum><header>Ensuring flexibility in inspection tools</header><text display-inline="no-display-inline">The Secretary shall update inspection processes and existing tools to advance a risk-based approach to evaluate, including conducting inspections, of establishments engaged in the manufacture, preparation, propagation, or processing of biosimilar biological products to enable the Food and Drug Administration to—</text><paragraph commented="no" display-inline="no-display-inline" id="idf0b9438a84c348ceab14afda08f4a62e"><enum>(1)</enum><text display-inline="yes-display-inline">increase utilization of remote regulatory assessments under section 704 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374</external-xref>), in accordance with the guidance issued by the Food and Drug Administration, titled <quote>Conducting Remote Regulatory Assessments—Questions and Answers</quote> (June 24, 2025) (or any successor guidance); and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1cb4dbdbff10463c9fd730c0b0a70f36"><enum>(2)</enum><text display-inline="yes-display-inline">maximize the use of alternative tools set forth in the guidance described in paragraph (1) to improve inspection efficiency.</text></paragraph></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="id19421888e6144f35af7d4c9f70784d66"><enum>5.</enum><header display-inline="yes-display-inline">FDA strategic plan on domestic inspection improvements for biosimilar biological facilities</header><text display-inline="no-display-inline">Not later than 1 year after the date of enactment of this Act, the Secretary shall develop and publish a strategic plan on ways the Food and Drug Administration will address challenges with respect to the inspection of domestic biosimilar biological product establishments, including regarding—</text><paragraph commented="no" display-inline="no-display-inline" id="id599a18424a874689a5f57a6223afe05b"><enum>(1)</enum><text display-inline="yes-display-inline">recruiting and retaining inspections staff;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1c31b2a54c354fc69033ce2722dc1f8e"><enum>(2)</enum><text display-inline="yes-display-inline">challenges specific to inspecting domestic biosimilar biological product establishments;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1f516ac76b9b402e93614e907602b5af"><enum>(3)</enum><text display-inline="yes-display-inline">improving internal communication among all Food and Drug Administration personnel involved in inspections of biosimilar biological product establishments; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idd3cbf1b1aca648df80b63a1c65f35726"><enum>(4)</enum><text display-inline="yes-display-inline">expanding opportunities for external communications with sponsors of applications under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>), including informing such sponsors about potential inspection requirements and resolving outstanding inspection related questions earlier in the review process.</text></paragraph></section></legis-body></bill>

